Fineline Cube

Follow:
14446 Articles
CompanyDeals

Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential

HutchMed's Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
CompanyDrug

HutchMed’s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline
CompanyDeals

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

CompanyDrug

Livzon Pharmaceutical’s Lecankitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis

CompanyDrug

TYK Medicines’ Asandeutertinib Wins NMPA Conditional Approval for EGFR-Mutant NSCLC with CNS Metastases

AbbVie Submits EMA Application for SKYRIZI Subcutaneous Induction in Crohn's Disease
CompanyDrug

AbbVie Submits EMA Application for SKYRIZI Subcutaneous Induction in Crohn’s Disease

TÜV Rheinland and United Imaging Sign Strategic Cooperation MoU to Accelerate Global Market Access for Medical Devices
CompanyDeals

TÜV Rheinland and United Imaging Sign Strategic Cooperation MoU to Accelerate Global Market Access for Medical Devices

CompanyDeals

ImmuneOnco Doses First Patient in Phase 2 Trial of IMM2510 Combo for First-Line HCC

Asieris Wins EU CE Certification for APLD-2304, the World's First Portable Single-Use Blue-Light Flexible Cystoscope
CompanyMedical Device

Asieris Wins EU CE Certification for APLD-2304, the World’s First Portable Single-Use Blue-Light Flexible Cystoscope

Policy / Regulatory

China Health Report: NHC Data Shows Life Expectancy at 79.25 Years as Health Spending Reaches 6.7% of GDP

Gilead's Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen
CompanyDrug

Gilead’s Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen

Roivant's Lisraya Wins FDA Approval as First Targeted Therapy for Dermatomyositis
CompanyDrug

Roivant’s Lisraya Wins FDA Approval as First Targeted Therapy for Dermatomyositis